Keyphrases
Rituximab
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Cytomegalovirus Infection
100%
Stem Cell Transplant Recipients
100%
Cytomegalovirus Reactivation
71%
Cytomegalovirus Viremia
42%
Transplantation
28%
Antiviral Drugs
14%
Disease Progression
14%
Viremia
14%
In(III)
14%
Median Time
14%
Clinical Suspicion
14%
Cytomegalovirus
14%
Chemotherapy Regimen
14%
Opportunistic Infections
14%
Cancer Institute
14%
1-year Follow-up
14%
Cancer Chemotherapy
14%
Cytomegalovirus Disease
14%
Fungal Infection
14%
Viremic
14%
Primary Disease
14%
Conditioning Regimen
14%
Infection Reactivation
14%
Candida Sepsis
14%
Medicine and Dentistry
Cytomegalovirus
100%
Cytomegalovirus Infection
100%
Rituximab
100%
Stem Cell Transplant
100%
Viremia
44%
Disease
22%
Disease Exacerbation
11%
Malignant Neoplasm
11%
Candidemia
11%
Opportunistic Infection
11%
Mycosis
11%
Allogeneic Stem Cell Transplantation
11%
Antivirus Agent
11%
Conditioning
11%
Cancer Chemotherapy
11%
Immunology and Microbiology
Cytomegalovirus Infection
100%
Cytomegalovirus
100%
Rituximab
100%
Stem Cell Transplant
100%
Viremia
40%
Opportunistic Infection
10%
Allogeneic Stem Cell Transplantation
10%
Conditioning
10%
Candida
10%
Pharmacology, Toxicology and Pharmaceutical Science
Cytomegalovirus
100%
Cytomegalovirus Infection
100%
Rituximab
100%
Viremia
44%
Disease
22%
Malignant Neoplasm
11%
Disease Exacerbation
11%
Opportunistic Infection
11%
Mycosis
11%
Antivirus Agent
11%
Cancer Chemotherapy
11%
Candidemia
11%
Neuroscience
Rituximab
100%
Stem Cell
100%
Cytomegalovirus
100%
Mycosis
8%
Antiviral Drug
8%